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Transcatheter aortic valve replacement (TAVR†) is a new technology that recently has been
shown to improve survival and quality of life in patients with severe symptomatic aortic steno-
sis who are not surgical candidates [1]. The development and design of transcatheter valves
has been ongoing for the past 20 years, and TAVR has now been approved by the FDA as
a treatment for aortic stenosis in patients who are not surgical candidates. In the United
States, there are currently two transcatheter valves available: the Edwards Sapien Valve
and the Medtronic CoreValve. While similar in some design elements, they also have char-
acteristic differences that affect both the mechanism of delivery as well as performance in
patients. This review aims to take a closer look at the development of this new technology,
review the published clinical results, and look toward the future of transcatheter valve ther-
apeutics and the challenges therein.
introduction
The aortic valve is one of four valves
in the human heart (Figure 1). It is located
between the left ventricle and aorta and in
99 percent of individuals is trileaflet in
structure (in 1 percent of cases it can be
bicuspid or unicuspid). During left ven-
tricular systole (contraction), the pressure
in the left ventricle increases until it rises
just  above  the  systolic  pressure  in  the
aorta. At this point in systole, the aortic
valve opens and blood exits the left ven-
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aorta. Thereafter, during left ventricular di-
astole (relaxation), the pressure in the left
ventricle  drops,  and  the  pressure  in  the
aorta forces the aortic valve back into its
closed position. There are two primary dis-
ease processes that can affect the aortic
valve: aortic insufficiency and aortic steno-
sis. In aortic insufficiency, also referred to
as aortic regurgitation, the aortic valve is
incompetent or leaky, and blood flows back
into the left ventricle from the aorta during
diastole. In aortic stenosis, the valve fails
to open fully, thereby creating a systolic
pressure gradient between the left ventricle
and aorta. Both of these disease processes
can contribute to progressive left ventricu-
lar dysfunction and symptomatic heart fail-
ure, adversely affecting patient morbidity
and mortality. 
Aortic stenosis is the most frequent type
of valvular heart disease in Western coun-
tries, with a prevalence of 2 percent in peo-
ple over the age of 65, 3 percent in people
over age 75, and 4 percent percent in peo-
ple over age 85 [2,3]. The disease is char-
acterized by a long latency period during
which patients remain symptom free, fol-
lowed by a rapid decline in functional sta-
tus and life expectancy after the appearance
of symptoms. The three classic symptoms
that  aortic  stenosis  may  manifest  are
angina,  syncope,  and  heart  failure  [4].
Medical treatment for severe symptomatic
aortic stenosis is not effective, and without
aortic valve replacement, the rate of mor-
tality is approximately 25 percent at 1 year
and 50 percent at 2 years [5,6]. We are en-
tering an era in medicine in which our pa-
tient population is older, and as a result, the
prevalence of aortic stenosis is increasing.
For many of these older patients, surgical
aortic valve replacement (SAVR) is a high-
risk procedure with significant morbidity
and mortality. Due to these risks, as well as
other important factors including depressed
left ventricular function and patient prefer-
ence, in clinical practice, 30 to 40 percent
of patients with symptomatic severe aortic
stenosis do not undergo surgery [7-9]. To
meet the medical needs of this population, a
new technology has emerged over the past
decade and is now being put into clinical
practice: transcatheter aortic valve replace-
ment. This technology has had significant
impacts throughout the heath care field with
the creation of a new biotechnology industry
around transcatheter valves, the creation of
multidisciplinary “heart teams” within clin-
ical practice, and the construction of hybrid
procedure rooms with both cath lab and op-
erating room capabilities. 
This review will focus on transcatheter
aortic valve replacement (TAVR1), a new
technology for the treatment of aortic steno-
sis in high and extreme risk surgical patients.
History oF tAVr
The first transcatheter aortic valve im-
plantations performed in animals were con-
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1Transcatheter aortic valve replacement (TAVR) and transcatheter aortic valve implantation (TAVI) are
used interchangeably throughout the literature and refer to the same procedure.
Figure 1. Anatomy of the human heart
demonstrating the four chambers (left and
right atria, and left and right ventricles) and
the four main valves (mitral, tricuspid, aortic,
and pulmonary). The aortic valve is located
between the left ventricle and aorta. (Image
provided by Medtronic, Inc.)ducted in 1992 by Dr. Andersen and col-
leagues [10]. It would be another 10 years
before Dr. Alan Cribier performed the first
in-man TAVR procedure in France in 2002
[11]. In this first case, Dr. Cribier and his
colleagues implanted a percutaneous heart
valve that consisted of three bovine peri-
cardial leaflets mounted within a tubular
stainless  steel  balloon-expandable  stent.
Prior to implantation, the stent-valve was
securely crimped onto a balloon catheter,
which was subsequently advanced across
the aortic valve. The balloon was then rap-
idly inflated and deflated, resulting in suc-
cessful deployment of the first transcatheter
aortic valve in man [11]. Since that first pa-
tient in 2002, there has been a rapid growth
within the field of structural heart disease
and transcatheter valve therapeutics. Five
years after Cribier’s first case, TAVR was
approved for use in Europe, and since then
more than 40,000 patients have been treated
worldwide with this technique, which is
now indicated as a treatment strategy for
both non-surgical patients and patients in
high surgical risk groups [1,12-14]. The re-
search and development of transcatheter
valves has evolved rapidly as a result of
these early successes, and there are cur-
rently at least eight valves in commercial
development. In the United States, two of
these valves are available: the balloon ex-
pandable Edwards Sapien prosthesis (Ed-
ward Lifesciences Inc: Irvine, CA; Figure
2a)  and  the  Medtronic  self-expanding
CoreValve ReValving System (Medtronic
Inc: Minneapolis, MN; Figure 2b).
design oF trAnscAtHeter 
Aortic VAlVes
Both the Edwards-Sapien Valve and the
Medtronic CoreValve are designed to func-
tion through a mechanism similar to a nor-
mally  functioning  human  tricuspid  aortic
valve. However, while both are trileaftlet in
design with a metallic framework for sup-
port, their construction as well as preparation
and delivery have significant differences.
The integrated Edwards-Sapien transcatheter
heart valve system is comprised of bovine
pericardial tissue made from three identical
sections of bovine pericardium that have
been preserved in buffered glutaraldehyde to
enable crosslinking of the tissue while pre-
serving flexibility and strength. The valve
tissue is affixed to a radiopaque stainless
steel stent frame within a fabric cuff at its in-
flow aspect and to attachment bars on the
commissural posts at its outflow aspect using
polytetrafluoroethylene (PTFE) sutures to
create a unidirectional trileaftlet tissue valve.
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Figure 2. A. Fully expanded Edwards Sapien Valve with its stainless steel frame and
trileaflet construction made from bovine pericardial tissue. (Published with permission from
Edward lifesciences Inc: Irvine, CA.) B. Fully expanded Medtronic CoreValve with its niti-
nol frame and trileaflet construction made from porcine pericardial tissue. (Image provided
by Medtronic, Inc. In the U.S., the Medtronic CoreValveﾮ System is available for investiga-
tional purposes only.)The tissue used for the Sapien valve is iden-
tical to that used on the popular Carpentier-
Edwards Perimount bioprosthetic valve used
for SAVR. Prior to delivery, the valve is
tightly compressed using a crimping mecha-
nism  onto  a  balloon  catheter.  The  com-
pressed  device  is  then  inserted  into  a
tip-deflecting catheter delivery system. Prior
to delivery, aortic balloon valvuloplasty is
performed, and thereafter the Sapien tran-
scatheter heart valve system is advanced up
the aorta and placed across the native aortic
valve. The balloon with the attached valve is
then rapidly inflated and deflated, expanding
and releasing the Sapien valve. The newly
functioning valve is passively secured to the
underlying native leaflets and to the aortic
annulus as a result of this delivery. There are
two sizes of the Sapien valve currently avail-
able, and they are 23mm and 26mm in di-
ameter.  The  23mm  valve  requires  a
22-French sheath, and the 26mm valve re-
quires a 24-French sheath for delivery [15]. 
In  contrast  to  the  Sapien  valve,  the
CoreValve is a self-expanding valve with a
Nitinol frame. Although the first generation
CoreValve (first implanted in humans in
2004)  was  also  made  from  bovine  peri-
cardium with an intra-annular valve function
similar to that of the Sapien valve, the cur-
rent  generation  CoreValve  is  made  from
porcine  (not  bovine)  pericardium.  The
choice  of  porcine  pericardium  for  the
CoreValve may be due in part to suggested
benefits that include diminished tissue thick-
ness  (thus  allowing  for  a  smaller  sheath
size), higher tensile strength, and tolerance
to bending, as well as less tissue elongation
providing for more consistent valve leaflet
coaptation [16]. 
The  choice  of  nitinol  as  opposed  to
stainless steel gives the CoreValve system
the ability to be loaded onto a catheter de-
livery system that does not require a balloon
and enables the valve to be gradually de-
ployed in stages. The unique properties of
nitinol, a metal alloy of nickel and titanium,
were first described by William Buehler and
Frederick Wang during research at the Naval
Ordnance Laboratory in 1962 [17]. Nitinol
exhibits  what  is  known  as  a  martensitic
transformation, which allows it to undergo
a reversible, solid state transformation. As a
result, at warmer temperatures (including
body  temperature),  nitinol  forms  a  very
strong, primitive cubic crystal structure re-
ferred  to  as  austenite  with  a  high  radial
strength. At colder temperatures, however,
such as when placed in an ice water bath,
nitinol transforms into a complex mono-
clinic crystal structure known as martensite.
At this lower temperature, nitinol exhibits
the property of superelasticity, giving it 10
to 30 times the elasticity of ordinary metal,
enabling the CoreValve metal stent frame to
be tightly compressed within the small de-
livery sheath required for the TAVR proce-
dure. Lastly, nitinol exhibits the property of
shape memory such that the shape of the
higher  temperature  austenite  is  “remem-
bered” despite the deformed shape that oc-
curs  at  the  lower  temperature,  and  thus,
when it is deployed in the warmer tempera-
ture of the body, it regains its original con-
figuration. 
clinicAl triAls witH tAVr
While both the Edwards Sapien and the
Medtronic CoreValve have been available
commercially in Europe for several years, in
the United States it has been only recently
that the Edwards Sapien valve has become
available for use outside of clinical trials (the
CoreValve is still only available through clin-
ical trials in the United States). U.S. Food
and Drug Administration (FDA) approval for
the Edwards Sapien valve, which occurred in
November 2011, came on the heels of the re-
cent publications of the PARTNER study
[1,12]. In the PARTNER study, there were
two cohorts of patients. Cohort A involved
699 patients with severe symptomatic aortic
stenosis who were at high risk for surgical
complications or death on the basis of co-
morbidities with a predicted risk of death of
at least 15 percent at 30 days after the proce-
dure. In cohort A, patients were randomized
in a 1:1 fashion to either SAVR or TAVR.
Cohort B involved 358 patients with severe
symptomatic aortic stenosis who were not
candidates for surgery due to coexisting con-
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dicted probability of 50 percent or more of
either death or significant morbidity 30 days
after surgery. In cohort B, patients were ran-
domized in a 1:1 fashion to either standard
medical therapy (including aortic valvulo-
plasty) or TAVR. For both cohorts, two car-
diac surgeons had to evaluate the patient and
agree that each patient was either not suitable
for surgery or was at high risk for surgical
complications based on the above criteria. 
In cohort A (Table 1), TAVR and SAVR
were found to be equivalent in overall mor-
tality at 1 year with a rate of death from any
cause of 24.2 percent following the TAVR
procedure  and  26.8  percent  following
SAVR. Although not statistically significant
(p = 0.07), the rate of major stroke following
the TAVR procedure was 5.1 percent vs. 2.4
percent following SAVR. There was a sig-
nificant difference in major vascular com-
plications that favored SAVR (11.5 percent
TAVR vs. 3.5 percent SAVR), while con-
versely, there was less major bleeding in
TAVR (14.7 percent TAVR vs. 25.7 percent
SAVR) and a trend toward a decreased inci-
dence of new onset of atrial fibrillation (12.1
percent TAVR and 17.1 percent SAVR) [12].
In cohort B (Table 2), the results of
which were published 8 months prior to co-
hort A, TAVR was found to be superior to
standard therapy in regard to death from any
cause (30.7 percent TAVR vs. 49.7 percent
from standard therapy) and repeat hospital-
ization (40 percent TAVR vs. 79 percent
standard  therapy)  at  1  year.  In  addition,
TAVR was associated with sustained im-
provement in New York Heart Association
(NYHA) class at 30 days, 6 months, and 1
year. At one year, however, TAVR was as-
sociated with an increased risk of major
stroke (7.8 percent vs. 3.9 percent), major
bleeding (22.3 percent vs. 11.2 percent), and
vascular complications (16.8 percent vs. 2.2
percent) [1]. In cohort B, patients in the stan-
dard therapy arm were treated both med-
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table 1. clinical outcomes in high-risk patients from the PArtner trial
(cohort A) randomized to either tAVr or sAVr.
outcome
30-day Mortality
1-year Mortality
Major Vascular Complications
New Atrial Fibrillation
New Pacemaker
Major Stroke at 1-year
Major bleed at 1-year
Transcatheter
AVR (TAVR)
N=348 
12 (3.4%)
84 (24.2%)
38 (11.0%)
42 (12.1%)
19 (5.7%)
17 (5.1%)
49 (14.7%)
Surgical AVR
(SAVR) 
N=351
22 (6.5%)
89 (26.8%)
11 (3.2%)
60 (17.1%)
16 (5.0%)
8 (2.4%)
85 (25.7%)
P-Value
0.07
0.44
<0.001
0.07
0.68
0.07
<0.001
table 2. clinical outcomes in extreme-risk patients from the PArtner trial
(cohort B) randomized to either tAVr or standard therapy.
outcome
30-day Mortality
1- year Mortality
Major Vascular Complications
New Atrial Fibrillation
New Pacemaker
Major Stroke at 1-year
Major bleed at 1-year
Transcatheter
AVR (TAVR)
N=179 
9 (5%)
55 (30.7%)
29 (16.2%)
1 (0.6%)
8 (4.5%)
14 (7.8%)
40 (22.3%)
Standard
Therapy
N=179
5 (2.8%)
89 (49.7%)
2 (1.1%)
3 (1.7%)
14 (4.8%)
7 (3.9%)
20 (11.2%)
P-Value
0.41
<0.001
<0.001
0.62
0.27
0.18
0.007ically and with aortic balloon valvuloplasty
if clinically indicated, with 37 percent of pa-
tients in the standard therapy arm undergo-
ing aortic balloon valvuloplasty. Based on
the results from cohort B of the PARTNER
study showing a dramatic improvement in 1
year mortality, in November 2011, the FDA
approved TAVR for patients with sympto-
matic severe aortic stenosis who are not sur-
gical candidates.
The CoreValve Pivotal U.S. Clinical
Trial is ongoing, and thus, the data available
for this device come from smaller European
studies and other registries. Three-year data
from the Italian CoreValve registry of 181
patients were recently published [18]. Sim-
ilar to the PARTNER study population, all
procedures were approved for use in patients
considered at high risk for surgery. All-cause
mortality was 23.6 percent at 1 year, similar
to 1-year mortality in PARTNER A of 24.2
percent (Table 3). As of January 2012, en-
rollment in the extreme risk surgical arm of
CoreValve U.S. Pivotal Trial had been com-
pleted, and it is expected that enrollment for
the high risk arm will be completed by the
fall of 2012.
comPAring tHe two VAlVes
While the outcomes in terms of survival
and symptom improvement are similar be-
tween comparable patient groups who un-
dergo TAVR with either the CoreValve or
Edwards Sapien Valve, there are notable dif-
ferences in complications seen in patients
treated with the two valves (Table 3). One
such difference between the CoreValve and
Sapien  Valve  is  the  need  for  permanent
pacemaker placement (PPM) after the pro-
cedure. The incidence of PPM placement
after CoreValve ranges from 12.1 percent in
the Italian registry to up to 39 percent in
other registries [19-22]. In contrast, the in-
cidence of need for PPM in the PARTNER
study with the Sapien Valve was 5.7 percent
and 4.5 percent in groups A and B respec-
tively, which was not different from those
patients treated either medically or surgi-
cally  [1,12].  The  increased  incidence  of
PPM placement after the CoreValve proce-
dure is due in part to the fact that the frame
of the CoreValve extends below the aortic
annulus and thus lays adjacent to the left
bundle branch. As a result, the His bundle
may be adversely affected during the ex-
pansion of the prosthesis due to the high ra-
dial force of the self-expanding nitinol frame
of the CoreValve [19].
While the structure and design of the
CoreValve leads to an increased need for PPM
placement, it also allows for the valve to be
more easily delivered and repositioned during
delivery.  In  contrast  to  the  Sapien  Valve,
which requires either a large 22 French or 24
French sheath for delivery, the CoreValve is
able to be delivered through an 18 French
sheath. Since the anatomy of many patients
cannot  accept  a  22  or  24F  sheath,  the
CoreValve can thus be used in many patients
who otherwise would not have been able to
tolerate the size of the Sapien delivery system.
As a result of the larger sheath size for deliv-
ery, there is an associated increase in vascular
complications seen with the Sapien Valve
(Table 3). The primary vascular access for
sheath placement and subsequent delivery of
both the CoreValve and Sapien valve is via the
femoral  artery;  however,  due  to  the  large
sheath sizes required, alternative access sites
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table 3. comparison of clinical outcomes in patients from the italian
coreValve registry and cohort A of the PArtner trial [12,18].
outcome
1- year Mortality
Major Vascular Complications
New Pacemaker
Major Stroke at 1-year
Italian CoreValve Registry [18]
N= 181
23.6%
3.3%
12.1%
3.4%
PARTNER Cohort A
TAVR [12]
N= 351
24.2%
11.0%
5.7%
5.1%are being investigated. These include direct
left ventricular apical access for the Sapien
Valve and both subclavian and direct aortic
access for the CoreValve. The outcomes from
these alternative access sites as compared to
femoral access have not been fully evaluated;
however,  data  from  studies,  including  the
STACCATO trial that compared the transapi-
cal approach for TAVR with the Sapien valve
against conventional SAVR, has raised con-
cerns about these alternative approaches [23]. 
The ability to adjust the positioning of
the valve during delivery gives the CoreValve
a distinct advantage over the Sapien Valve.
Due to the self-expanding nature of the Niti-
nol frame of the CoreValve, the CoreValve
can be deployed in stages allowing for subtle
adjustments in position during the deploy-
ment  phases  (Figure  3).  In  contrast,  the
Sapien Valve is rapidly deployed with a sin-
gle balloon expansion that does not allow for
repositioning either during or after deploy-
ment (Figure 4). 
conclusions
In the design, development, and now clin-
ical application of both the Edwards Sapien
Valve and Medtronic CoreValve, we are wit-
ness to a new era in the field of valvular heart
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Figure 3. stepwise desheathing deploy-
ment mechanism of medtronic
coreValve system. A shows the valve
completely collapsed within the delivery
sheath. B and c show the gradual expan-
sion of the nitinol framed valve as the deliv-
ery sheath is slowly retracted. During this
stage of deployment, the valve is still at-
tached to the delivery catheter and can be
repositioned or even completely recaptured
and removed. d shows the final release of
the valve from the delivery sheath. With the
valve now fully released from the sheath, it
can no longer be easily adjusted. (Image
provided by Medtronic, Inc. In the U.S., the
Medtronic CoreValveﾮ System is available
for investigational purposes only.)
Figure 4. rapid balloon deployment
mechanism of edwards sapien system.
A shows the crimped valve loaded onto the
balloon delivery catheter. B shows the
valve being deployed by rapid balloon infla-
tion. With deflation of the balloon, the valve
maintains its configuration and the balloon
catheter can then be removed leaving be-
hind the fully functioning Sapien Valve.
(Published with permission from Edward
lifesciences Inc: Irvine, CA.)disease. However, despite the advances within
this arena, there remain significant hurdles to
overcome. These include addressing the in-
crease in stroke observed in the PARTNER
study, the aforementioned increased incidence
in permanent pacemaker placement for pa-
tients getting the CoreValve, the ability to
reposition if needed, as well as issues of alter-
native  access  in  patients  whose  femoral
anatomy cannot accommodate the large sheath
sizes required for the transfemoral approach.
Significant research and product development
is currently ongoing to addresses each of these
issues, including the use of cerebral protection
devices similar to those used in carotid proce-
dures, the use of smaller devices, and the de-
sign  of  retrievable  devices,  as  well  as
alternative access techniques including sub-
clavian, apical, and direct aortic access. There
are no fewer than six other transcatheter valve
types currently being evaluated, each of which
employs unique features aimed to improve the
design and function of this technology. Lastly,
as modifications and improvements are made
to the design, the medical field must continue
to adapt and develop in response to this new
technology. New recommendations and expert
consensus documents are being developed to
help guide the use of this new technology [24]. 
We are no longer in an era in which the old
boundaries between cardiac specialties apply.
To obtain the best outcome for the patient, there
must be a true collaboration between the car-
diothoracic surgeon and interventional cardiol-
ogist, not only in evaluation of the patient but in
the procedure itself. Just as with the develop-
ment of the valve design, the development of
the “heart valve team” will take time but is just
as critical for the success of this technology.
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